Journal Options Oncology

Course Directors: Robert S. Mocharnuk, MD

Browse Journal Options by Topic

View Collections

Featured Expert Commentary

Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia

Susan M. O'Brien, MD

Professor of Medicine
Department of Leukemia
University of Texas M.D. Anderson Cancer Center
Houston, Texas

Recent Articles

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Estey E, Garcia-Manero G, Ferrajoli A, et al.
Blood. 2006;107:3469-3473.
Capsule Summary | Abstract
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.
Mounier N, Spina M, Gabarre J, et al.
Blood. 2006;107:3832-3840.
Capsule Summary | Abstract
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
Attal M, Harousseau JL, Leyvraz S, et al.
Blood. 2006;108:3289-3294.
Capsule Summary | Expert Commentary | Abstract | Slides
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Chanan-Khan A, Miller KC, Musial L, et al.
J Clin Oncol. 2006;24:5343-5349.
Capsule Summary | Expert Commentary | Abstract | Slides
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI, Kouroukis CT, White D, et al.
J Clin Oncol. 2007;25:1570-1575.
Capsule Summary | Expert Commentary | Abstract | Slides
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Forstpointner R, Unterhalt M, Dreyling M, et al.
Blood. 2006;108:4003-4008.
Capsule Summary | Expert Commentary | Abstract | Slides
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
Harousseau JL, Attal M, Leleu X, et al.
Haematologica. 2006;91:1498-1505.
Capsule Summary | Expert Commentary | Abstract | Slides
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 Trial.
Moorman AV, Harrison CJ, Buck GA, et al.
Blood. 2007;109:3189-3197.
Capsule Summary | Expert Commentary | Abstract | Slides
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S, Moore JO, Boyd TE, et al.
J Clin Oncol. 2007;25:1114-1120.
Capsule Summary | Expert Commentary | Abstract | Slides
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
Walker R, Barlogie B, Haessler J, et al.
J Clin Oncol. 2007;25:1121-1128.
Capsule Summary | Expert Commentary | Abstract | Slides